Biliary Atresia Treatment Market Analysis & Forecast: 2026-2033

Biliary Atresia Treatment Market Size and Share Analysis – 2026 To 2033

The global Biliary Atresia Treatment Market size is anticipated to grow at a CAGR of approximately 7.7%, reaching around USD 1,320 Mn in 2026 and is expected to further expand to approximately USD 2,220 Mn in 2033. The market growth is primarily driven by increasing incidence of neonatal liver disorders, rising awareness for early diagnosis through newborn screening programs, advancements in the Kasai procedure and liver transplantation outcomes, and expanding availability of specialized pediatric hepatology care across developed and emerging healthcare systems. According to the NIH Genetic and Rare Diseases (GARD) program, biliary atresia is a leading cause of pediatric end-stage liver disease requiring liver transplantation, thereby supporting increasing demand for specialized surgical and transplant-based treatment pathways.

Key Takeaways

• Type III is expected to dominate with 55% clinical burden share in 2026. This is because Type III biliary atresia represents complete extrahepatic bile duct obstruction, which leads to faster progression toward liver fibrosis and end-stage liver disease. According to the multicenter study published in BMC Medical Genomics reported that Type III cases comprised 89% of all biliary atresia patients, confirming it as the overwhelmingly dominant anatomical subtype across populations
• Surgery segment is likely to dominate the market with 65% share in 2026. The segment’s dominance is driven by the clinical requirement of Kasai portoenterostomy as the first-line intervention and the growing reliance on liver transplantation in progressive or late-diagnosed cases. According to the American Liver Foundation, biliary atresia is the most common indication for pediatric liver transplantation, reinforcing the strong procedural demand for surgical care.
• North America is expected to acquire the prominent share of 38% in2026. The region’s supremacy is driven by its excellent pediatric healthcare infrastructure, high liver transplant activity and strong early diagnosis ecosystem that directly drive the demand for biliary atresia treatment. According to the U.S. Organ Procurement and Transplantation Network (OPTN), the United States undertakes around 500–600 children liver transplants every year. Biliary atresia is the leading cause of pediatric liver transplantation.

Market Drivers

Shift Toward Early Diagnosis, Surgical Innovation & Transplant Expansion is Transforming the Biliary Atresia Treatment Market

The global Biliary Atresia therapy Market is mainly driven by increased focus on early diagnosis, improved surgical outcomes and growth in liver transplantation infrastructure, which are helping in improving the survival rates and adoption of therapy internationally. The enhanced integration of newborn screening programs and improved imaging technology have led to earlier diagnosis of biliary atresia, and consequently earlier treatment with the Kasai portoenterostomy technique, and slower development to end-stage liver disease.

According to the National Institutes of Health (NIH) indicate that early Kasai surgery, before 60 days of infancy, considerably increases native liver survival rates, strongly impacting therapy adoption patterns and increasing procedural volumes across specialist pediatric institutions.

Current Events and Their Impact on the Biliary Atresia Treatment Market

Uncover macros and micros vetted on 75+ parameters: Get instant access to report

Segmental Insights 

To learn more about this report, Request Free Sample

Why is Type III Dominating the Biliary Atresia Treatment Market?

On the basis of disease type, Type III biliary atresia is projected to account for the largest clinical burden share of 55% in 2026. The segment’s dominance is owing to its anatomical severity, as Type III represents complete extrahepatic bile duct obstruction, which leads to rapid progression toward liver fibrosis and end-stage liver disease. This increases the need for early surgical intervention and liver transplantation.

In addition, a multi-hospital cohort study involving 851 patients reported that Type III biliary atresia represents 97.9% of cases, thereby reinforcing its dominance as the most severe and most frequently encountered subtype globally.

In July 2024, researchers from Henan Children’s Hospital / Children’s Hospital Affiliated to Zhengzhou University (China) published a study in Scientific Reports (Nature Portfolio) introducing a plasma metabolomics-based diagnostic model for biliary atresia.

Surgery Segment holds the Largest Market Share 

To learn more about this report, Request Free Sample

On the basis of treatment type, the Surgery segment is projected to account for the largest market share of 65% in 2026. The segment’s dominance is driven by the clinical requirement of Kasai portoenterostomy as the first-line intervention and the growing reliance on liver transplantation in progressive or late-diagnosed cases, making surgical intervention the cornerstone of disease management.

Additionally, a 2024 study published in the American Journal of Transplantation, although biliary complications are seen in 20-30% of the cases after transplantation, the advancements in surgical techniques and immunosuppressive therapy have resulted in significant improvements in long-term graft survival outcomes, which has been a driving factor for the sustained dominance of surgical management in this market.

In February 2026, Mayo Clinic clinical guidance reiterated that the Kasai portoenterostomy remains the primary first-line surgical management of biliary atresia, with optimal outcomes when performed before 60 days of birth.

Biliary Atresia Treatment Market Trends

• Minimally invasive and robotic Kasai portoenterostomy is an emerging surgical breakthrough that is enhancing perioperative results. In a multicenter study published in 2026 in Frontiers in Surgery (Children’s Hospital of Soochow University, China), robotic Kasai surgery showed significantly less intraoperative blood loss (30-40% less than open surgery) and better early recovery parameters (faster oral feeding, shorter ICU stay). However, operating duration was still longer than traditional surgery (≈310 versus 200 min).
• Sequential kasai-to-transplant method is now the chosen treatment pathway in advanced instances. A 2025 BMC Pediatrics study of 300 patients indicated that patients receiving Kasai prior to liver transplantation had superior pre-transplant clinical stability and rates of post-transplant problems compared to primary transplantation, with the potential for hybrid treatment approaches.
• Precision diagnostics and biomarker testing are driving more accurate early detection. A 2024 metabolomics study in Scientific Reports (Nature) revealed 327 distinct metabolites with diagnostic accuracy (AUC 0.96-0.97) for biliary atresia, showing great momentum for non-invasive diagnostic technologies to replace delayed invasive confirmation approaches.

Regional Insights

To learn more about this report, Request Free Sample

By 2026, the Biliary Atresia Treatment Market share in the North America region is expected to be around 38%. The region’s rise can be attributed to the presence of a well-developed pediatric healthcare infrastructure, a large network of pediatric liver transplant centers, attractive reimbursement systems, and high adoption of early diagnosis programs for neonatal liver disorders. In the U.S. and Canada, the existence of dedicated pediatric hepatology centers still helps in early intervention with Kasai portoenterostomy and liver transplantation.

According to the OPTN/SRTR 2024 Annual Data Report, the United States completed a record 11,458 liver transplants in 2024, a significant increase over prior years, driven by the nation’s expanding transplant infrastructure and organ availability.

In February 2025, the American Academy of Pediatrics (AAP) released new clinical guidance to improve the early identification of biliary atresia in infants across the United States.

Asia Pacific Biliary Atresia Treatment Market Trends

The Asia Pacific region is expected to witness the fastest growth in the Biliary Atresia Treatment Market during the forecast period. The region’s growth is driven by rising awareness of pediatric liver diseases, increasing healthcare expenditure, expansion of pediatric transplant programs, and growing adoption of newborn screening initiatives across China, Japan, South Korea, and India.

According to findings published in the World Journal of Pediatric Surgery and highlighted by News-Medical.net on October 8, 2025, the Japanese Biliary Atresia Registry analyzed 3,899 patients diagnosed between 1989 and 2021, making it one of the largest biliary atresia registries globally.

Early Detection Initiatives and Expanding Pediatric Liver Care Infrastructure are Accelerating the Market in the United States

The U.S. biliary atresia treatment market is growing at a steady pace owing to increasing focus on early diagnosis, expansion of pediatric liver transplant programs and improved clinical care of neonatal cholestatic diseases. The country has a highly specialized network of pediatric hepatology and transplant centers which enable rapid intervention with Kasai portoenterostomy and liver transplantation.

According to the American Academy of Pediatrics (AAP) reports that biliary atresia accounts for over 60% of liver transplants in infants less than one year and nearly 30% of all pediatric liver transplants, underscoring the high treatment burden and continued need for surgical therapy.

In October 2024, the American Liver Foundation (ALF) launched the Bili the Brave™ Toolkit for children living with biliary atresia and their families.

China Biliary Atresia Treatment Market Trends

China Biliary Atresia Treatment Market is expected to develop due to increase in investments in pediatric liver disease research, advancements in diagnostic technologies and availability of specialist pediatric hepatobiliary surgery institutions. The country is a major contributor to global biliary atresia research and clinical innovation.

According to the study published in the World Journal of Pediatrics in November 2025 developed and validated an AI-driven diagnostic system for early biliary atresia detection.

Who are the Major Companies in Biliary Atresia Treatment Industry

Some of the major key players in Biliary Atresia Treatment Market are AstraZeneca plc, Eisai Co., Ltd., Mirum Pharmaceuticals, Inc., Pfizer Inc., Albireo Pharma, Inc., Novartis AG, Alkem Labs, and Glenmark Pharmaceuticals.

Key News

• In March 2025, Takeda Pharmaceutical Company and Mirum Pharmaceuticals announced that Japan’s Ministry of Health, Labour and Welfare approved LIVMARLI (maralixibat) oral solution for cholestatic pruritus in patients with ALGS and PFIC.
• In October 2025, Ipsen announced that it would present scientific data across five rare liver diseases, including biliary atresia, at The Liver Meeting 2025 hosted by the American Association for the Study of Liver Diseases (AASLD).

Market Report Scope 

Analyst Opinion

• Technological advancements in surgical treatment are leading to better patient outcomes and driving market expansion. Data from the Japanese Biliary Atresia Registry released in 2025 demonstrated a decrease in the median age at Kasai portoenterostomy from 77 to 56 days and an improvement in 20-year overall survival from 61.7% to 87.6% over time. These gains indicate the effect of earlier diagnosis, improved surgical procedures and better postoperative care on long-term survival.
• One of the major growth drivers of the biliary atresia treatment market is expected to be the increased adoption of newborn screening programs. Studies from the national stool color card screening program in Taiwan have shown that early screening can significantly boost prompt diagnosis and raise the success rate of Kasai portoenterostomy. Native liver survival is of utmost importance for early detection, and so newborn screening programs are an important field of interest for healthcare systems all over the world.
• Growing global collaboration in pediatric liver disease research is improving clinical outcomes and building a more robust therapeutic ecosystem. The European Reference Network on Hepatological Diseases (ERN RARE-LIVER) says international registries and collaborative research projects are enabling for a better awareness of rare pediatric liver ailments including biliary atresia. These activities include promoting consistent treatment standards, more patient monitoring and a faster adoption of innovative therapeutic choices across a variety of locations.

Market Segmentation

• By Disease Type (Revenue, USD Mn, 2021-2033)
  • Type I
  • Type II
  • Type III
• By Treatment Type (Revenue, USD Mn, 2021-2033)
  • Medications
  • Bile Acids
  • Antibiotics
  • Corticosteroids
  • Surgery
• By Region (Revenue, USD Mn, 2021-2033)
  • North America
    • U.S.
    • Canada
  • Latin America
    • Brazil
    • Mexico
    • Argentina
    • Rest of Latin America
  • Europe
    • Germany
    • U.K.
    • France
    • Italy
    • Spain
    • Russia
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • ASEAN
    • Rest of Asia Pacific
  • Middle East
    • GCC
    • Israel
    • Rest of Middle East
  • Africa
    • South Africa
    • Central Africa
    • North Africa

Sources

Primary Research Interviews

• Pediatric Hepatologists
• Pediatric Gastroenterologists
• Pediatric Liver Transplant Surgeons
• Neonatologists & Pediatric Specialists
• Hospital Administrators & Transplant Coordinators
• Rare Disease Researchers
• Pharmaceutical & Biotechnology Companies
• Academic Medical Centers
• Others

Databases

• Bloomberg Terminal
• Thomson Reuters Eikon
• S&P Global Market Intelligence
• FactSet
• PitchBook
• D&B Hoovers
• Crunchbase
• Others

Magazines

• Liver Transplantation Magazine
• Hepatology News
• Rare Disease Advisor
• Medical Economics
• Healthcare Business Today
• PharmaVoice
• Others

Journals

• American Journal of Transplantation
• Journal of Pediatric Surgery
• Hepatology
• Journal of Hepatology
• BMC Pediatrics
• World Journal of Pediatric Surgery
• Scientific Reports (Nature Portfolio)
• Pediatric Transplantation
• Others

Newspapers

• Financial Times
• The Wall Street Journal
• Reuters
• Bloomberg News
• The Economic Times
• Business Standard
• China Daily
• Others

Associations

• American Liver Foundation
• American Academy of Pediatrics
• American Association for the Study of Liver Diseases
• European Society for Paediatric Gastroenterology Hepatology and Nutrition
• Organ Procurement and Transplantation Network
• Scientific Registry of Transplant Recipients
• European Reference Network RARE-LIVER
• Others

Public Domain Sources

• National Institutes of Health (NIH) – Genetic and Rare Diseases Information Center (GARD)
• Centers for Disease Control and Prevention (CDC)
• Organ Procurement and Transplantation Network (OPTN)
• Scientific Registry of Transplant Recipients (SRTR)
• National Center for Biotechnology Information (NCBI)
• World Health Organization (WHO)
• American Academy of Pediatrics (AAP)
• Others

Proprietary Elements

• CMI Data Analytics Tool
• Proprietary CMI Existing Repository of Information for the Last 10 Years